123 results on '"Zile, Michael"'
Search Results
2. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long‐term outcomes
3. Interatrial shunt therapy in advanced heart failure: Outcomes from the open‐label cohort of the RELIEVE‐HF trial
4. Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON‐HF study
5. Independent prognostic importance of blood urea nitrogen (BUN) to creatinine ratio in heart failure
6. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
7. Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
8. Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction
9. Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan
10. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with HFrEF and HFpEF
11. Clinical characteristics of HFrEF patients with rare pathogenic variants in DCM ‐associated genes: a subgroup analysis of the PARADIGM‐HF trial
12. Incremental prognostic value of biomarkers in PARADIGM‐HF
13. Health‐related quality of life outcomes in PARAGON‐HF
14. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials
15. Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
16. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF
17. Angiotensin‐neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure
18. Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF
19. Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial
20. Effect of sacubitril/valsartan versus enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
21. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE
22. Serum potassium in the PARADIGM-HF trial
23. Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM‐HF analysis
24. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial
25. INTERVENE‐HF: feasibility study of individualized, risk stratification‐based, medication intervention in patients with heart failure with reduced ejection fraction
26. Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction
27. Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial
28. Prediction of worsening heart failure events and all‐cause mortality using an individualized risk stratification strategy
29. Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF
30. Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF
31. Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real‐world population
32. Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance
33. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction
34. The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE
35. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction
36. The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes
37. Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: 'Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial' by Bocchi et al
38. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
39. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
40. The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes
41. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas
42. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
43. Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium
44. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I‐PRESERVE) trial
45. Suppressing angiotensinogen synthesis attenuates kidney cyst formation in aPkd1mouse model
46. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response
47. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy
48. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study
49. SPARC Facilitates Inflammation in the Aging Heart and Suppresses Macrophage M2 Polarization
50. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.